Radius Health Inc
NASDAQ:RDUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hangcha Group Co Ltd
SSE:603298
|
CN |
|
Honda India Power Products Ltd
NSE:HONDAPOWER
|
IN |
|
Xiangpiaopiao Food Co Ltd
SSE:603711
|
CN |
Radius Health Inc
Depreciation & Amortization
Radius Health Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Radius Health Inc
NASDAQ:RDUS
|
Depreciation & Amortization
$96.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Radius Health Inc
Glance View
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company is headquartered in Boston, Massachusetts and currently employs 293 full-time employees. The company went IPO on 2014-06-06. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
See Also
What is Radius Health Inc's Depreciation & Amortization?
Depreciation & Amortization
96.3m
USD
Based on the financial report for May 31, 2025, Radius Health Inc's Depreciation & Amortization amounts to 96.3m USD.
What is Radius Health Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
3%
Over the last year, the Depreciation & Amortization growth was 1%. The average annual Depreciation & Amortization growth rates for Radius Health Inc have been 11% over the past three years , 11% over the past five years , and 3% over the past ten years .
